市場調查報告書

急性疼痛 - 市場洞察,流行病學,預測

Acute Pain - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 905943
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
急性疼痛 - 市場洞察,流行病學,預測 Acute Pain - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

本報告提供主要7個國家(英國,德國,法國,義大利,西班牙,日本)的急性疼痛市場調查,市場概要,疾病概要和現行的治療方法,新藥的簡介,以總及各國的市場趨勢,流行病學的預測,市場規模,患者數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 急性疼痛市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 急性疼痛:疾病背景和概要

  • 簡介
  • 急性疼痛的種類
  • 急性疼痛的原因
  • 急性疼痛的症狀
  • 急性疼痛的病理生理學
  • 急性疼痛的診斷

第4章 流行病學和患者人口

  • 主要7個國家的急性疼痛的總患者數
  • 主要7個國家的急性疼痛的患者數:病情

第5章 美國的流行病學

  • 假設和根據
  • 急性疼痛的總患者數
  • 急性疼痛的患者數:各重症度

第6章 歐洲5個國家的流行病學

  • 假設和根據
  • 德國
    • 急性疼痛的總患者數
    • 急性疼痛的患者數:各重症度
  • 法國
  • 義大利
  • 西班牙
  • 英國

第7章 日本的流行病學

  • 假設和根據
  • 急性疼痛的總患者數
  • 急性疼痛的患者數:各重症度

第8章 治療流程與現行治療

  • 急性止痛與管理
    • 藥理學性
    • 非藥理學性
  • 急性手術後疼痛的治療流程
  • 急性疼痛的提倡指南

第9章 未滿足需求

第10章 已上市產品

  • LICART(Diclofenac Epolamine):IBSA Institut Biochimique SA/帝國製藥
    • 產品說明
    • 法規的里程碑
    • 臨床開發活動
    • 安全性和有效性
    • 產品簡介
  • DSUVIA (Sufentanil):AcelRx Pharmaceuticals
  • APADAZ:KemPharm
  • Zalviso:AcelRx Pharmaceuticals
  • Tivorbex (Indomenthacin):Iroko Pharmaceuticals
  • Clinical Trial Information
  • Zorvolex (Diclofenac):EGALET
  • OXECTA:King Pharmaceuticals Inc.
  • EXPAREL:Pacira Pharmaceuticals
  • ZIPSOR:Depomed
  • Nucynta:Ortho-McNeil-Janssen
  • OFIRMEV:Mallinckrodt
  • ULTRACET:Janssen Pharms

第11章 新藥

  • 關鍵交叉競爭
  • Ubrogepant:Allergan
    • 產品說明
    • 開發趨勢
    • 臨床開發活動
    • 臨床試驗資訊
    • 安全性和有效性
    • 產品簡介
  • Oliceridine injection (TRV130):Trevena
    • 開發趨勢
    • 臨床開發
    • 臨床試驗資訊
  • HTX-011:Heron Therapeutics
  • CL-108:Charleston Laboratories
  • Dexketoprofen Tramadol:Menarini Group
  • MR308:Mundipharma Research GmbH & Co KG/Laboratorios del Dr. Esteve, S.A.
  • CR845:Cara Therapeutics
  • Capsaicin/Diclofenac:Boehringer Ingelheim
  • Ibuprofen:Boehringer Ingelheim
  • Methoxyflurane:Medical Developments International Limited
  • CA-008:Concentric Analgesics
  • VX-150:Vertex Pharmaceuticals Incorporated
  • CL-H1T:Charleston Laboratories
  • Tolperisone:Neurana Pharmaceuticals
  • NTM-001:Neumentum Pharmaceuticals

第12章 主要7個國家的急性疼痛市場

  • 市場規模(以金額為準)
  • 市場規模(以數量為準)

第13章 美國:市場預測

  • 美國
    • 總市場規模(以金額為準)
    • 總市場規模(以數量為準)
    • 市場規模:各治療藥物

第14章 歐洲5個國家:市場預測

  • 德國
    • 總市場規模(以金額為準)
    • 總市場規模(以數量為準)
    • 市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國

第15章 日本:市場預測

  • 日本
    • 總市場規模(以金額為準)
    • 總市場規模(以數量為準)
    • 市場規模:各治療藥物

第16章 市場成長要素

第17章 市場障礙

第18章 附錄

  • 調查手法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章:關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0668

DelveInsight's "Acute Pain - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Pain, historical and forecasted epidemiology as well as the Acute Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute Pain market report provides current treatment practices, emerging drugs, Acute Pain market share of the individual therapies, current and forecasted Acute Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acute Pain Disease Understanding and Treatment Algorithm

The DelveInsight Acute Pain market report gives a thorough understanding of the Acute Pain by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Acute Pain.

Treatment

It covers the details of conventional and current medical therapies available in the Acute Pain market for the treatment of the condition. It also provides Acute Pain treatment algorithms and guidelines in the United States, Europe, and Japan.

Acute Pain Epidemiology

The Acute Pain epidemiology division provide insights about historical and current Acute Pain patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Acute Pain Epidemiology

The epidemiology segment also provides the Acute Pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Acute Pain Drug Chapters

Drug chapter segment of the Acute Pain report encloses the detailed analysis of Acute Pain marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Acute Pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Acute Pain treatment.

Acute Pain Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Acute Pain treatment.

Acute Pain Market Outlook

The Acute Pain market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Acute Pain market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Acute Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Acute Pain market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Acute Pain market in 7MM.

The United States Market Outlook

This section provides the total Acute Pain market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Acute Pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Acute Pain market size and market size by therapies in Japan is also mentioned.

Acute Pain Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Acute Pain market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Pain Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute Pain key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Acute Pain emerging therapies.

Reimbursement Scenario in Acute Pain

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Acute Pain domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Acute Pain market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Acute Pain Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Acute Pain, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Acute Pain epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute Pain are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Acute Pain market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Pain market

Report Highlights

  • In the coming years, Acute Pain market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Acute Pain. Launch of emerging therapies will significantly impact the Acute Pain market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acute Pain
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acute Pain Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acute Pain Pipeline Analysis
  • Acute Pain Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Pain Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Acute Pain Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Acute Pain Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Acute Pain market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Acute Pain total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Acute Pain market size during the forecast period (2017-2030)?
  • At what CAGR, the Acute Pain market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Acute Pain market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Acute Pain market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Acute Pain?
  • What is the historical Acute Pain patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Acute Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute Pain?
  • Out of all 7MM countries, which country would have the highest prevalent population of Acute Pain during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Acute Pain treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Acute Pain in the USA, Europe, and Japan?
  • What are the Acute Pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acute Pain?
  • How many therapies are developed by each company for Acute Pain treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Acute Pain treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Acute Pain therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Pain and their status?
  • What are the key designations that have been granted for the emerging therapies for Acute Pain?
  • What are the global historical and forecasted market of Acute Pain?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute Pain market
  • To understand the future market competition in the Acute Pain market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Pain in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Pain market
  • To understand the future market competition in the Acute Pain market

Table of Contents

1. Key Insights

2. Executive Summary of Acute Pain

3. Competitive Intelligence Analysis for Acute Pain

4. Acute Pain: Market Overview at a Glance

  • 4.1. Acute Pain Total Market Share (%) Distribution in 2017
  • 4.2. Acute Pain Total Market Share (%) Distribution in 2030

5. Acute Pain: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Acute Pain Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Acute Pain Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Acute Pain Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Acute Pain Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Acute Pain Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Acute Pain Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Acute Pain Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Acute Pain Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Acute Pain Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Acute Pain Treatment and Management
  • 8.2. Acute Pain Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Acute Pain Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Acute Pain: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Acute Pain Market Size in 7MM
  • 13.3. Acute Pain Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Acute Pain Total Market Size in the United States
    • 15.1.2. Acute Pain Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Acute Pain Total Market Size in Germany
    • 15.3.2. Acute Pain Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Acute Pain Total Market Size in France
    • 15.4.2. Acute Pain Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Acute Pain Total Market Size in Italy
    • 15.5.2. Acute Pain Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Acute Pain Total Market Size in Spain
    • 15.6.2. Acute Pain Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Acute Pain Total Market Size in the United Kingdom
    • 15.7.2. Acute Pain Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Acute Pain Total Market Size in Japan
    • 15.8.3. Acute Pain Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Acute Pain

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Acute Pain Epidemiology (2017-2030)
  • Table 2 : 7MM Acute Pain Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Acute Pain Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Acute Pain Epidemiology in Germany (2017-2030)
  • Table 6 : Acute Pain Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Acute Pain Epidemiology in France (2017-2030)
  • Table 8 : Acute Pain Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Acute Pain Epidemiology in Italy (2017-2030)
  • Table 10 : Acute Pain Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Acute Pain Epidemiology in Spain (2017-2030)
  • Table 12 : Acute Pain Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Acute Pain Epidemiology in the UK (2017-2030)
  • Table 14 : Acute Pain Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Acute Pain Epidemiology in Japan (2017-2030)
  • Table 16 : Acute Pain Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Acute Pain Epidemiology (2017-2030)
  • Figure 2 : 7MM Acute Pain Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Acute Pain Epidemiology in the United States (2017-2030)
  • Figure 4 : Acute Pain Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Acute Pain Epidemiology in Germany (2017-2030)
  • Figure 6 : Acute Pain Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Acute Pain Epidemiology in France (2017-2030)
  • Figure 8 : Acute Pain Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Acute Pain Epidemiology in Italy (2017-2030)
  • Figure 10 : Acute Pain Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Acute Pain Epidemiology in Spain (2017-2030)
  • Figure 12 : Acute Pain Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Acute Pain Epidemiology in the UK (2017-2030)
  • Figure 14 : Acute Pain Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Acute Pain Epidemiology in Japan (2017-2030)
  • Figure 16 : Acute Pain Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)